Update on COVID-19 Treatment: A triple combination antiviral therapy shows favourable results in a Phase-2 randomised clinical trial.

Clinical trial study, COVID-19 Medication, Pharmacovigilance,

In an open label, randomised, phase 2 clinical trial, triple combination of interferon beta-1b (an injectable interferon), lopinavir–ritonavir (oral protease inhibitor) and ribavirin (oral nucleoside analogue) were shown safe and superior to monotherapy with lopinavir‑ritonavir. This triple combination shown efficacy in shortening virus shedding, alleviating symptoms, and facilitating discharge of COVID-19 patients with mild to…

Read More

Highlights of Remdesivir (A potential treatment for COVID-19?)

COVID-19 Medication, Drug Safety Updates, Pharmacovigilance, , , , , , , ,

Remdesivir (GS-5734) is being developed by Gilead Sciences, an American biopharmaceutical company based in California with a primary therapeutic focus in antiviral medicines. Remdesivir is an antiviral drug (broad spectrum) under clinical trial investigation for the treatment of COVID-19 (coronavirus disease). Remdesivir gained public attention due to publication of some of its clinical study results…

Read More

Hydroxychloroquine: A potential therapy for COVID-19?

Clinical trial study, Drug Safety Updates, Global Safety Alerts, Safety Communications, USFDA-United States of America, ,

Coronavirus disease 2019 (COVID-19), a global pandemic which is affecting human beings with an acute respiratory infectious illness by damaging multiple organ systems, including heart, lung, and blood. Most adults with COVID-19 experience fever, cough, and fatigue and then recover within one to three weeks. However, it becomes fatal for some patients who develop severe…

Read More

error: Content is protected !!